{"filings":[{"id":483036,"accession_number":"0001493152-26-024095","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2026-05-18T12:56:23+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evofem Q1 net loss $5.5M ($0.04/sh) vs prior net income; sales rise to $0.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $5.5M ($0.04 per share) vs net income $1.0M ($0.01 per share) in Q1 2025.","Net sales $0.9M, up ~12.5% from $0.8M in Q1 2025; driven by higher WAC and improved gross-to-net.","Operating expenses $5.5M after excluding a one-time $5.6M R&D reduction from trade payables settlement.","Entered distribution agreement for SOLOSEC in Sub-Saharan Africa with Clovis Davis Pharmaceuticals.","UAE regulatory review ongoing; pricing certificates for PHEXX obtained; NIH-funded Phase 4 trial enrolling patients."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":899000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94127,"accession_number":"0001493152-26-020417","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Evofem signs exclusive 5-year distributorship for SOLOSEC in sub-Saharan Africa with Clovis Davis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive 5-year distribution agreement with Clovis Davis for SOLOSEC in sub-Saharan Africa, effective April 24, 2026.","SOLOSEC is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.","Clovis Davis to lead distribution, promotion, and sales; regulatory filings based on US FDA dossier.","BV affects ~25% of women in sub-Saharan Africa; 10.9M women eligible in Ethiopia alone.","No upfront payments or financial terms disclosed; partnership aims to expand global reach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94126,"accession_number":"0001493152-26-017082","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem Biosciences extends maturity of Adjuvant convertible notes by six months","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth Amendment to Securities Purchase Agreement dated April 10, 2026 with Adjuvant Global Health Technology Fund.","Notes now due six months after April 10, 2026 (approx. Oct 10, 2026), or upon change of control or acceleration.","No prepayment of notes allowed before that six-month date without Adjuvant's prior written consent.","Amendment updates maturity definition in Section 3.1 of the Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106269,"accession_number":"0001493152-26-011613","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Evofem and Windtree mutually terminate PHEXXI supply agreement, no fees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["License and Supply Agreement for PHEXXI manufacturing terminated March 13, 2026, by mutual consent.","Windtree had not established required manufacturing capabilities; no termination fees payable.","Windtree must return all Evofem confidential information and property; survival provisions remain.","Agreement originally entered March 20, 2025, and amended March 28, 2025, now terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106268,"accession_number":"0001493152-26-009689","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Evofem reports FY2025 net sales $20.2M (+4% YoY), income from operations $3.4M vs loss $7.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record net sales of $20.2M in FY2025, fifth consecutive year of growth; up 4% from $19.4M in FY2024.","Income from operations of $3.4M in FY2025 vs loss of $7.7M in FY2024; net income of $0.3M vs net loss of $9.0M.","Reduced total operating expenses by 38% to $16.8M, including gains from vendor settlement and royalty liability change.","Q4 2025 net sales of $9.6M (+35% YoY); operating income of $3.3M vs loss of $1.0M; net income of $2.8M vs loss of $3.0M.","Since Oct 2025: targeting 55-60% manufacturing cost reduction for PHEXX and SOLOSEC; UAE pricing certificates received."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106267,"accession_number":"0001493152-26-001886","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Evofem posts updated corporate slide deck; no material news disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filing under Item 7.01 confirms distribution of slide presentation to investors.","No specific financial or operational updates, guidance changes, or product news.","Presentation is available on the company's website; no material new information.","Company undertakes no obligation to update the materials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122578,"accession_number":"0001493152-25-025172","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Evofem stockholders approve reverse stock split (1:500–1,500) and elect four directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split of Common Stock at ratio between 1:500 and 1:1,500, with Board discretion to implement by Nov 2026.","Four directors elected to Class I/II: Kamdar, Rutherford, Rarick, O'Brien; each received over 167M votes for.","Say-on-pay and 2025 Equity Incentive Plan both approved; BPM LLP ratified as auditor.","Series E-1 and G-1 preferred stockholders unanimously voted for reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122577,"accession_number":"0001493152-25-022318","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evofem posts Q3 2025 operating income of $1.0M; net sales up 10% YoY to $5.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $5.0M in Q3 2025 vs $4.5M Q3 2024; operating income $1.0M vs loss of $2.4M.","Net loss attributable to common stockholders $1.7M ($0.01 per share) vs $2.4M ($0.02) prior year.","Total operating expenses decreased 42% to $4.0M, helped by $1.9M gain from change in Rush royalty estimate.","Terminated merger with Aditxt after stockholders did not approve the deal at Oct 20 special meeting.","Advancing manufacturing cost reduction targeting ~50% lower COGS for both PHEXX and SOLOSEC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":10622000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122576,"accession_number":"0001493152-25-018687","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["1.02","5.07","7.01","9.01"],"status":"ready","headline":"Evofem shareholders reject merger with Aditxt; merger terminated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders voted against merger: 93.2M for, 7.2M against; proposal not approved at Special Meeting on Oct 20, 2025.","Evofem terminates Merger Agreement with Aditxt effective Oct 20, 2025; no termination fee paid.","Company pivots to seek national stock listing and growth capital, targeting sustainable positive EBITDA in 2027.","CEO states collaboration with Aditxt for Mitomic diagnostic tests continues under September 2024 agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122575,"accession_number":"0001493152-25-018454","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem extends Adjuvant convertible note maturity to April 2026; prepayment restricted","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Notes become due on earliest of: 6 months after Oct 13, 2025 (April 13, 2026), change of control, or acceleration.","No prepayment permitted before April 13, 2026 without Adjuvant's written consent.","Amendment dated October 13, 2025 modifies the October 2020 Securities Purchase Agreement.","Adjuvant Global Health Technology Fund holds the convertible promissory notes covered by the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139261,"accession_number":"0001641172-25-025530","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["1.01","5.03","3.03","9.01"],"status":"ready","headline":"Evofem Biosciences amends merger agreement with Aditxt, exchanges $1.573M notes for Series G-1 Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sixth Amendment to A&R Merger Agreement updated definitions to include Series G-1 Preferred, set dissenting share cap at 5,932,818 common shares and 202 preferred shares.","Exchanged $1.573M aggregate principal of senior secured convertible notes for 1,573 Series G-1 Preferred shares (stated value $1,000/share, conversion price $0.0154).","Series G-1 Preferred carries voting rights (as-converted), monthly dividends in stock or PIK, and trigger-event conversion at alternative prices with 25% premium.","Amendment requires waivers from all Series E-1 Preferred holders on price adjustment and other provisions, and updated exchange agreement for convertible noteholders.","Merger with Aditxt remains pending; proxy statement to be filed for shareholder vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139260,"accession_number":"0001641172-25-023740","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evofem Biosciences Reports Q2 2025 Net Sales of $4.8M, Improves Loss from Operations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales rose 16% to $4.8M in Q2 2025 from $4.2M in Q2 2024, driven by SOLOSEC addition and PHEXXI price increase.","Loss from operations improved to $1.3M in Q2 2025 versus $1.4M in the prior year quarter.","Raised $2.4M net in April and June 2025 from sale of senior subordinated notes and warrants to Aditxt (ADTX).","PHEXXI submitted for UAE marketing approval by licensee Pharma 1; SOLOSEC submission expected Q3 2025.","Net loss per share was $(0.02) in Q2 2025 vs net income of $0.02 per share in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":5670000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139259,"accession_number":"0001641172-25-017563","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Evofem Biosciences issues $1.42M convertible notes and warrants to Aditxt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal amount $1,423,076.92; warrants to purchase 92,407,592 shares.","Aditxt paid ~$650 per $1,000 principal; net proceeds ~$925,000.","Notes bear 8% interest (12% upon default), mature June 26, 2028.","Conversion/exercise price $0.0154 per share; 9.99% beneficial ownership cap.","Warrants exercisable immediately, expire in 5 years, allow cashless exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156831,"accession_number":"0001641172-25-011962","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Evofem signs exclusive SOLOSEC license for UAE, Kuwait, Saudi Arabia and other Middle East countries","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive 5-year license to develop, market, and sell SOLOSEC in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.","Pharma 1 targets mid-2025 regulatory submission in UAE; must file within 3 months of agreement.","Consideration includes upfront payment, regulatory milestones, and sales-based milestones; supply at cost-plus.","SOLOSEC is FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.","Expands existing Evofem-Pharma 1 partnership beyond PHEXXI to SOLOSEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156830,"accession_number":"0001641172-25-010526","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evofem Q1 net income $1.0M, revenue $0.8M; plans 55-60% PHEXXI COGS cut","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $0.8M, down 78% from $3.6M YoY due to order timing after Q4 2024 stocking.","Net income $1.0M ($0.01 basic EPS) vs net loss $4.9M ($0.16 loss) in Q1 2024.","Partnered with Windtree to reduce PHEXXI manufacturing cost by 55-60%; Evofem bears no tech transfer costs.","Received $1.5M in April from sale of notes/warrants to Aditxt under merger agreement.","Cash and restricted cash $1.1M at March 31, 2025; new U.S. patent for SOLOSEC extends to 2040."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":845000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156829,"accession_number":"0001641172-25-009248","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem Biosciences amends supply agreement with UAE partner to add 3-Pack product size","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Amendment adds 3-applicator package size (3-Pack) to existing Development and Supply Agreement with Pharma 1 Drug Store L.L.C.","Pricing for 3-Pack is firm through Dec 31, 2025; specific price redacted as confidential.","Mixed-size batches (3-Pack and 12-Pack) allowed at Licensor-approved ratios; additional packaging costs paid by Licensee.","Order lead time remains at least six months; batch size is 96,000 applicators.","All other terms of the original July 17, 2024 agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156828,"accession_number":"0001641172-25-004599","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem issues $1.15M convertible notes to Aditxt as part of merger financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued $1,153,846 principal in senior subordinated convertible notes and warrants to buy 74,925,075 shares to Aditxt.","Net proceeds of ~$750,000 from partial close on April 8; Aditxt paid $650 per $1,000 principal.","Notes bear 8% interest (12% default), mature April 8, 2028, convertible at $0.0154 per share; warrants at same price.","Waived Aditxt default for missing $1.5M Fifth Parent Investment; second half must close by April 16 or merger can end.","Aditxt obtained call option from Adjuvant to buy convertible notes for $13M, contingent on senior debt satisfaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156827,"accession_number":"0001641172-25-002583","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem amends PHEXXI supply agreement with Windtree; adjusts pricing, forecast, and termination rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase price set at $15 per 12-count box for first 3 years or until tech transfer costs recovered.","Binding forecast period adjusted to 4 months; Buyer can reduce orders up to 20% within that period without penalty.","If supply chain disruptions persist 90 days, Buyer may terminate agreement with no further liability.","Two instances of non-conforming product in 12 months allows Buyer termination.","Supplier's liability capped at greater of $1M or 12 months of payments, excluding certain breaches."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175235,"accession_number":"0001641172-25-000742","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem signs manufacturing deal to cut PHEXXI cost ~55-60%; extends merger close to Sept 2025 with $1.5M investment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Windtree to manufacture PHEXXI; Evofem expects COGS reduction of 55-60%.","No cost to Evofem for tech transfer; Windtree engaged a manufacturer.","Fifth Amendment extends merger consummation date to Sept 30, 2025.","Aditxt must invest $1.5M by April 7, 2025 via F-1 preferred or notes.","Evofem to use best efforts to hold shareholder meeting by Sept 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175234,"accession_number":"0001641172-25-000209","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Evofem reports 2024 net sales up 6% to $19.4M; operating loss improved 57% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2024 net sales $19.4M (+6% YoY); operating loss $7.7M vs $17.8M in 2023, improvement of 57%.","Q4 2024 net sales $7.1M vs $4.8M Q4 2023; Q4 operating loss $1.0M vs $3.4M.","Sales & marketing expense fell to 47% of net sales for FY2024, down from 64% in 2023.","Merger with Aditxt: $1.5M funding due by Apr 7, 2025; stockholder meeting by Sep 26, 2025; close by Sep 30, 2025.","Raised $2.7M from Aditxt in Oct 2024; used to pay FDA obligations; year-end restricted cash $0.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175233,"accession_number":"0001493152-25-001682","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Evofem receives OTCQB delisting notice for trading below $0.01 for 30 days; 90-day cure period until April 6, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received OTC notice on Jan 6, 2025: closing bid price below $0.01 for 30 consecutive days violates Minimum Bid Price Requirement.","Has 90-day compliance period until April 6, 2025 to regain compliance by having bid price >= $0.01 for 10 consecutive trading days.","Failure to regain compliance by April 6, 2025 will result in removal of common stock from OTCQB.","Company says it will monitor bid price and consider available options to resolve deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192185,"accession_number":"0001493152-24-051174","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Evofem cancels special meeting, withdraws proposals from Sept 23 proxy","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Cancelled previously announced special meeting of stockholders on Dec 23, 2024.","Withdrew all stockholder proposals from the preliminary proxy filed Sept 23, 2024.","No reason for cancellation or new meeting date disclosed in the filing.","Ticker EVFM trades on OTCQB; impact of cancellation on corporate actions unclear."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192184,"accession_number":"0001493152-24-047613","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem extends merger outside date with Aditxt to Jan 31, 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Fourth Amendment to Amended and Restated Merger Agreement dated Nov 19, 2024.","Changes required consummation date from Nov 29, 2024 to Jan 31, 2025.","Amendment modifies only Section 8.1(b)(ii); all other terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192183,"accession_number":"0001493152-24-046043","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evofem Biosciences Q3 2024 operating loss narrows to $2.4M; acquires SOLOSEC, licenses Phexxi in Middle East","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $4.5M in Q3 2024, down 12% YoY from $5.1M; operating loss improved 31% to $2.4M.","Net loss attributable to common stockholders $2.4M ($0.02/sh) vs net income $66.0M ($15.34/sh) in Q3 2023 due to prior-year debt extinguishment gain.","Acquired global rights to SOLOSEC (secnidazole) 2g oral granules, FDA-approved for BV and trichomoniasis, relaunched as single-dose treatment.","Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; UAE regulatory submission on track by year-end 2024.","Aditxt invested $5.0M since May 2024, including $1.3M in Q3 and $2.7M in October 2024, under amended merger agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":12259000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192182,"accession_number":"0001493152-24-043757","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Evofem secures voting agreements for Aditxt merger; Aditxt completes $2.28M preferred investment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Evofem signed voting agreements with Series E-1 stockholders and convertible noteholders to vote in favor of merger with Aditxt subsidiary Adifem.","Aditxt completed $2.28M final preferred investment (Series F-1), meeting $5M total commitment under A&R Merger Agreement since May 2024.","Closing conditions require majority stockholder vote and Aditxt raising ~$17M, including ~$15.2M to satisfy Evofem's senior secured noteholder.","If Aditxt fails to secure funds, senior secured noteholder expected to block closing; no assurance conditions will be met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192181,"accession_number":"0001493152-24-043241","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["1.01","1.02","2.04","9.01"],"status":"ready","headline":"Evofem gets merger support pacts; secured lenders terminate forbearance, declare default","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Institutional investors with rights to ~1.09B common shares (via preferred, convertible notes, warrants) agreed to vote for Aditxt merger.","Forbearance agreement terminated Oct 27 after Designated Agent (Future Pak) sent Amended Notice of Default citing new defaults, including HHS obligations.","Default allows secured lenders to accelerate debt and exercise remedies under the SPA; prior forbearance covered only specified defaults.","Company's merger with Aditxt (via Merger Sub) still pending; debt default may affect closing or require renegotiation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192180,"accession_number":"0001493152-24-042605","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Evofem raises $2.28M via private placement of Series F-1 Preferred Stock to Aditxt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aditxt purchased 2,280 Series F-1 Preferred Stock shares for $2,280,000 in a private placement.","Shares are convertible into common stock; company granted registration rights for resale.","Private placement closed Oct 28, 2024; exempt from registration under Section 4(a)(2) of Securities Act.","Part of consideration for A&R Merger Agreement with Aditxt, as previously disclosed.","Company filed Registration Rights Agreement to register conversion shares within 300 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192179,"accession_number":"0001493152-24-039392","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.01","2.04","3.02","9.01"],"status":"ready","headline":"Evofem receives $106.8M debt acceleration notice; closes $460K private placement with Aditxt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Future Pak LLC (agent) claims Event of Default under SPA; repurchase price ~$106.8M if all Purchasers exercise Section 5.7 Option.","Evofem 'strongly disagrees' with default claim and intends to vigorously contest it.","Closed private placement with Aditxt: 460 shares Series F-1 Preferred for $460,000; registration rights granted.","Third Amendment to Merger Agreement adjusts Aditxt equity investment: 720 shares due Oct 2, 2280 shares due Oct 31.","Merger sub (Adifem) to merge into Evofem; Evofem to become wholly owned subsidiary of Aditxt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208671,"accession_number":"0001493152-24-038113","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Evofem Biosciences sells $260k Series F-1 Preferred Stock to Aditxt in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 260 shares of Series F-1 Preferred Stock to Aditxt for $260,000 on September 20, 2024.","Preferred shares are convertible into common stock; registration rights agreement requires filing within 300 days.","Private placement is part of consideration under the Amended Merger Agreement with Aditxt (previously disclosed).","Securities issued in reliance on Section 4(a)(2) exemption from registration under the Securities Act.","Company must use best efforts to have registration statement declared effective within 90 days of filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208670,"accession_number":"0001493152-24-035285","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem and Aditxt amend merger agreement again; extend equity investment and closing deadlines","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Third Parent Equity Investment date moved from Sept 6 to Sept 30, 2024; Fourth from Sept 30 to Oct 31, 2024.","Outside consummation date (Section 8.1(b)(ii)) extended to November 29, 2024.","Aditxt must purchase $1.5M of Series F-1 preferred stock on each of the new Third and Fourth investment dates.","No other changes to merger terms; previous conditions and consideration unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208669,"accession_number":"0001493152-24-034623","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Evofem receives OTCQB delisting notice for bid price below $0.01","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received OTC Markets notice on Aug 28, 2024 for bid price below $0.01 for 30 consecutive trading days.","Has 90-day compliance period until Nov 26, 2024 to regain minimum bid price requirement.","Compliance can be met if bid price is at least $0.01 for 10 consecutive trading days.","Failure to comply by Nov 26 will result in removal of common stock from OTCQB.","Company will monitor and consider available options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208668,"accession_number":"0001493152-24-033265","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem and Aditxt amend merger, extend third equity investment deadline contingent on Aditxt raising $20M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Third Parent Equity Investment deadline moved to earlier of Sep 6, 2024 or 5 business days after Aditxt closes a ≥$20M public offering.","Aditxt must purchase 2,000 shares of Evofem Series F-1 Preferred for $2,000,000 on that date.","Other investment dates unchanged: $500k (Jul 12), $500k (Aug 9), $1,000k (Sep 30).","Amendment signed Aug 16, 2024 by CEOs of Evofem (Saundra Pelletier) and Aditxt (Amro Albanna)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208667,"accession_number":"0001493152-24-031835","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evofem Q2 net sales up 69% to $4.2M; operating loss improves 81% to $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $4.2M (+69% YoY); net income $1.3M ($0.02/share) vs net loss $8.6M ($5.43) in prior year.","Operating expenses down 43% to $5.5M; operating loss improved 81% to $1.4M.","Acquired global rights to SOLOSEC (secnidazole) for bacterial vaginosis and trichomoniasis.","Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; partnered with Hello Alpha.","Received $2.0M from Aditxt related to merger; targeting late 2024 close."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7763000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208666,"accession_number":"0001493152-24-028818","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Evofem licenses Phexxi to Pharma 1 for Middle East; closes $500K private placement with Aditxt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive 5-year license for Phexxi in UAE, Kuwait, Saudi Arabia, Qatar and other Middle East countries.","Pharma 1 to file UAE regulatory submission in Q3 2024; UAE contraceptive market projected $185.1M by 2030.","Pharma 1 pays cost-to-manufacture plus fee; must maintain at least 4 months of inventory at all times.","Evofem closed $500K private placement with Aditxt via 500 shares of Series F-1 Preferred Stock.","Merger with Aditxt targeting September 30, 2024 closing; amended merger agreement dated July 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208665,"accession_number":"0001493152-24-028352","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Evofem acquires Solosec from Lupin for up to $84M in contingent consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Evofem (OTCQB: EVFM) acquired Solosec (secnidazole) from Lupin Inc.; deal closed July 14, 2024.","Potential total consideration up to $84 million based on future contingent milestones; plus assumption of certain liabilities.","Solosec is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.","Acquisition complements Evofem's women's health portfolio, which includes Phexxi; Evofem also in merger with Aditxt (ADTX)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208664,"accession_number":"0001493152-24-028348","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Evofem, Aditxt sign amended merger with $1.8M cash and preferred stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aditxt to pay up to $1.8M cash for Evofem common stock, less dissenting shares; preferred stock exchange also specified.","Aditxt commits to purchase $4M of Evofem Series F-1 Preferred Stock in staged tranches by Sept 30, 2024.","Merger conditions include shareholder approvals, warrant exchanges, and $150K cap on warrant cash-outs.","Evofem board unanimously recommends merger; proxy statement to be filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208663,"accession_number":"0001493152-24-028280","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Evofem posts updated corporate slide presentation; no specific financial or operational details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made current investor slide deck available on its website as of July 17, 2024.","No material new information, guidance, or financial figures identifiable from the filing text.","Presentation furnished under Item 7.01 and not deemed filed for SEC purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226396,"accession_number":"0001493152-24-025289","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Evofem amends Series F-1 Preferred; conversion price set at $0.0154, adjustment provisions removed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended Certificate of Designation removes Section 8(h) adjustment provisions from Series F-1 Preferred.","Conversion Price changed to $0.0154 per share; previously subject to adjustment.","Approved by unanimous written consent of Required Holders.","Filed with Delaware Secretary of State on June 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226395,"accession_number":"0001493152-24-019433","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Evofem Q1 net sales down 38% to $3.6M; loss narrows; Aditxt merger progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $3.6M vs $5.8M a year ago, attributed to WAC increase cycle and Change Healthcare cyberattack.","Loss from operations narrowed 21% to $2.8M; total operating expenses decreased 31% to $6.4M.","Received $1M from Aditxt in May; Aditxt to invest additional $2.5M by July 1, 2024; merger expected H2 2024.","USPTO allowed new Phexxi composition-of-matter patent; fifth U.S. patent covering the drug.","Medi-Cal rebate reduced 7.4% effective July 1, 2024, improving net pricing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":3603000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226394,"accession_number":"0001493152-24-017598","cik":1618835,"company_name":"Evofem Biosciences, Inc.","ticker":"EVFM","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Evofem reinstates merger with Aditxt after termination, secures $1M payment and new terms","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["On May 2, Evofem, Aditxt and merger sub reinstated the merger agreement after termination on April 26.","Aditxt made a $1M initial payment; must invest up to $2.5M in Series F-1 Preferred via subsequent capital raises by July 1.","Termination date extended from May 8 to July 15, 2024; no-shop provision eliminated.","Evofem granted termination rights if $1M not paid by May 3 or interim milestones missed.","Evofem waived Aditxt's prior non-compliance with initial equity investment obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":927710.4964539007,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}